The life sciences industry faced numerous challenges in 2022 due to the pandemic, a turbulent economy, and a shrinking biotech bubble. However, there was positive momentum around diversity, equity, and inclusion (DE&I) and the integration of paradigm-shifting tech. As the industry heads towards a new year, PharmaVoice asked pharma leaders about the key areas of focus for 2023. These include diversity in clinical trials, the hottest tech, cultivating innovation, talent management, patient engagement, and leadership in uncertain times. The trends are likely to have a significant impact on pharma leaders’ strategic focus in the coming year. The magazine will unveil its “crystal ball” outlook on various other trends in January. The insights from industry thought leaders will provide guidance on how to navigate the challenges of the life sciences industry in 2023.